Search General Info
Search Education
Search Partnering Companies
![BIF](/sites/default/files/2023-05/230112-bio-bif-logo-color-horiz.jpg)
Heartseed is a biotech company developing iPSC-derived purified cardiomyocytes for heart failure. Founded by Professor Keiichi Fukuda, the world leading physician scientist in the field of cardiac regenerative medicine, Heartseed has raised $40MM since its foundation in 2015 including the recent Series B in 2019.
The company's lead pipeline, HS-001 can be safely transplanted into patient's myocardium because of is >99% purity achieved by our proprietary metabolic selection technologies. Compared with previous cell therapy products, higher response rate and higher efficacy in cardiac functional improvement are expected as HS-001 grow and electrically synchronized with other cells within the myocardium.
First-in-Human trial of HS-001 was approved by Keio University Review Committee in early 2020 and will be initiated in late 2020. Company-sponsored Ph1/2 trial will also be initiated in 2021.
Out-licensing discussion is ongoing for ex-Japan market.
The company's lead pipeline, HS-001 can be safely transplanted into patient's myocardium because of is >99% purity achieved by our proprietary metabolic selection technologies. Compared with previous cell therapy products, higher response rate and higher efficacy in cardiac functional improvement are expected as HS-001 grow and electrically synchronized with other cells within the myocardium.
First-in-Human trial of HS-001 was approved by Keio University Review Committee in early 2020 and will be initiated in late 2020. Company-sponsored Ph1/2 trial will also be initiated in 2021.
Out-licensing discussion is ongoing for ex-Japan market.
![](/sites/default/files/hubb_images/2996/attachments/%2520-%2520f1_Heartseed_20Inc__508d8af3.png)
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Japan
Year Founded:
2015
Main Therapeutic Focus:
Cardiovascular
Lead Product in Development:
HS-001, allogeneic iPSC-derived cardiomyocyte spheroids
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
![photo](/act-root/bio/assets/images/profile-default.png)
BIO DOUBLE HELIX SPONSORS
![Sanofi logo](/sites/default/files/2022-05/Sanofi_Color_jpg_Double%20Helix.jpg)
![Eli Lilly and Company](/sites/default/files/2019-09/Eli%20Lilly%20and%20Company.png)
![Amgen logo](/sites/default/files/2022-05/Amgen_Color_png_Double%20Helix.png)
![Genentech logo](/sites/default/files/2022-05/Genentech_Color_png_Double%20Helix.png)
![Merck_logo_2022](/sites/default/files/2022-10/Merck_Color_.png)
![Avantor](/sites/default/files/2021-06/Avantor-BIO-DH-578.png)
![GSK logo](/sites/default/files/2023-04/gsk_color_png.png)
BIO HELIX SPONSORS
![Johnson and Johnson](/sites/default/files/2021-06/Johnson-Johnson-BIO-DH-578.png)
![Takeda logo](/sites/default/files/2022-05/Takeda_Color_jpg_Premier.jpg)
![Travere logo](/sites/default/files/2022-05/Travere_Color_png_Helix%20large.png)
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved